Synertec Corporation (ASX:SOP) Lands $45.5m ANSTO Engineering Contract

Sonal Goyal

14 September 2026 06:44 PM AEST

Synertec Corporation (ASX:SOP) Lands $45.5m ANSTO Engineering Contract

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Synertec Corporation has been awarded a $45.5 million engineering services contract with ANSTO for its Nuclear Medicine Manufacturing Program at Lucas Heights, NSW.
The contract runs for approximately 8 years and is valued at 2.4 times Synertec Engineering's FY26 external revenue.
An initial 26-month design phase, commencing 21 September 2026, is expected to generate approximately $36 million in revenue.
Synertec expects the contract to deliver a contribution Margin above 25% and be cumulatively Cash Flow positive for more than 90% of its term.

Synertec Corporation Limited (ASX:SOP) has been awarded a $45.5 million engineering services contract with the Australian Nuclear Science and Technology Organisation (ANSTO), covering process design and design integration work on ANSTO's Nuclear Medicine Manufacturing Program at Lucas Heights, New South Wales. The contract runs for approximately 8 years and represents 2.4 times Synertec Engineering's FY26 external revenue.

Scope and Structure of the ANSTO Contract

Under the contract, Synertec will act as Process Design and Design Integration lead for the Nuclear Medicine Manufacturing Program, with a scope covering process design, systems engineering, facility-wide design integration, regulatory support, commissioning support, GMP and radiological manufacturing systems, procurement support, and digital engineering services. The initial design phase of the project, expected to run for 26 months, commences 21 September 2026 and is anticipated to generate approximately $36 million in Revenue for Synertec.

Synertec said the contract is expected to deliver a contribution margin in excess of 25%, with gross labour margin at the top end of the company's target range. The company also expects the contract to be cumulatively cash flow positive for more than 90% of its term, with only minimal Working Capital requirements, which it says can be serviced from existing Debt Facility headroom and its recent Equity raise.

Strategic Significance for Synertec

Managing Director Michael Carroll said the company was “delighted to now identify ANSTO as our client,” adding that the award “reflects Synertec's capability in highly regulated environments.” The company said the contract positions Synertec as a centre of facility design and integration expertise, validates its strategy of diversifying across industries and expanding geographically, and is expected to strengthen its positioning across the nuclear and healthcare sectors while accelerating the growth of its New South Wales operations. Synertec said it expects to provide an update to its FY27 revenue guidance as mobilisation progresses and greater clarity emerges on the project's execution profile.

Conclusion

The ANSTO contract is a significant win for Synertec Corporation (ASX:SOP), both in scale, at 2.4 times its FY26 external revenue, and in the strategic credibility it lends the company within highly regulated nuclear and healthcare-adjacent engineering work. With mobilisation set to begin on 21 September 2026 and an initial 26-month design phase expected to generate around $36 million in revenue, the coming reporting periods should provide an early indication of how smoothly the contract is being executed. Shareholders may want to watch for the flagged FY27 revenue guidance update as mobilisation progresses, as that will offer a clearer picture of how the contract is expected to flow through Synertec's financials over its roughly 8-year term.

FAQs

Q: What contract has Synertec Corporation been awarded?

A: Synertec has been awarded a $45.5 million engineering services contract with ANSTO, acting as Process Design and Design Integration lead for the Nuclear Medicine Manufacturing Program at Lucas Heights.

Q: How long does the contract run and how much is the initial phase worth?

A: The contract runs for approximately 8 years, with an initial 26-month design phase, commencing 21 September 2026, expected to generate approximately $36 million in revenue.

Q: How significant is this contract relative to Synertec's existing business?

A: The contract is valued at 2.4 times Synertec Engineering's FY26 external revenue, making it a substantial addition to the company's order book.

Q: What margins and cash flow does Synertec expect from the contract?

A: The company expects a contribution margin above 25%, gross labour margin at the top end of its target range, and cumulative positive cash flow for more than 90% of the contract term.

Q: What work will Synertec perform under the contract?

A: Synertec's scope covers process design, systems engineering, facility-wide design integration, regulatory and commissioning support, GMP and radiological manufacturing systems, procurement support, and digital engineering services.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.